Bicara CMO Sells Shares, Investors Unfazed

David Raben, Bicara Therapeutics CMO, sold 5,500 shares, earning $126,000, reducing his direct holdings by 9%. Despite this, he retains 41,913 options. The sale is seen as routine liquidity, with Bicara, a Boston biotech, developing bifunctional antibodies for solid tumors. The company posted a $137.95 million full-year 2025 net loss, but shares surged 54.57% over the past year. First-quarter 2026 results, due May 11, will focus on pipeline progress amid high hopes for oncology breakthroughs. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/f89109736b07ba5e